ABT vs NERV · P/E 25, rev $44.33B vs P/E 2.2, $12.4M cap
Abbott Laboratories (ABT) versus Minerva Neurosciences Inc (NERV) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Minerva Neurosciences Inc (NERV) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
NERV does not have a complete income-statement cache yet.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. NERV currently screens at market cap $12.4M and trailing P/E 2.2.
Not investment advice. Open the ABT and NERV stock pages for the full models.
Not investment advice.